Company: SYRA
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-022023
Chunk: 91

Company: Syra Health Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 2
Chunk 91
---
 $97,890 of rent incurred in both periods from STVentures, LLC, an entity beneficially owned by our principal owners,
our management team and their affiliates, $104,117 and $136,007 of software expense, $345,152 and $443,233 of insurance, $24,558 and
$119,322 of investor relations, and $77,234 and $83,489 of subscription and membership fees for the nine months ended September 30, 2025
and 2024, respectively.

Depreciation

We
incurred $18,171 of depreciation expense for the nine months ended September 30, 2025, compared to $55,460 of depreciation expense for
the nine months ended September 30, 2024, a decrease of $37,289, or 67%.

Other
Income (Expense)

Other
income, on a net basis, consisted of $8,992 of interest incurred on insurance finance charges, offset by $15,892 of interest income,
for the nine months ended September 30, 2025. Other expense, on a net basis, consisted of $10,072 of interest incurred on insurance finance
charges, offset by $18,448 of interest income, for the nine months ended September 30, 2024. Other expense, on a net basis, decreased
by $1,476, or 18%, primarily due to decreased interest income compared to the prior period.

Net
Loss

Our
net loss for the nine months ended September 30, 2025 was $761,763, compared to a net loss of $3,254,841 for the nine months ended September
30, 2024, a decrease of $2,493,078.

Liquidity
and Capital Resources

We
believe that our existing sources of liquidity, along with cash expected to be generated from sales and services, will not be sufficient
to fund our operations, anticipated capital expenditures, working capital and other financing requirements for at least the next twelve
months from the issuance of the financial statements included elsewhere in this annual report. In the event we are unable to achieve
profitable operations in the near term, we may require additional equity and/or debt financing; however, we cannot provide assurance
that such financing will be available to us on favorable terms, or at all. We will continue to monitor our expenditures and cash flow
position.

The
following table summarizes total current assets, liabilities, accumulated deficit and